혈장 분획제제 시장 규모, 점유율, 동향 및 예측 : 유형, 용도, 최종 사용자, 지역별(2026-2034년)

The global blood plasma derivatives market size was valued at USD 50.8 Billion in 2025. Looking forward, IMARC Group estimates the market to reach USD 78.1 Billion by 2034, exhibiting a CAGR of 4.76% from 2026-2034. North America currently dominates the market, holding a market share of over 48.9% in 2025. The rising chronic disease prevalence, advanced plasma collection infrastructure, technological innovations, growing geriatric population, and expanding therapeutic applications are some of the factors driving the market growth in this region.

Blood plasma derivatives are concentrates of specific proteins prepared from plasma that are obtained through fractionation process. Factor VIII, immunoglobulin, albumin, hyperimmune globulin, factor IX and fresh frozen are some of the common blood plasma derivatives. They are rich in proteins, minerals, salts, hormones, vitamins and protease inhibitors, due to which they are widely used to kill viruses that cause hepatitis B, hemophilia A, bleeding disorders, immunodeficiency, hepatitis C, hypogammaglobulinemia, hemophilia B and human immunodeficiency virus (HIV). Apart from this, blood plasma derivatives assist in enhancing nutrition, controlling body temperature and coagulation of blood, maintaining osmotic pressure, enhancing respiration and excretion, and regulating acid-base balance. Blood plasma derivatives are commonly stored at hospitals, clinics, diagnostic centers and blood transfusion centers.

Blood Plasma Derivatives Market Trends:

The increasing geriatric population that are more susceptible to developing infectious diseases are creating a positive outlook for the market. Blood plasma contains immunoglobulins that play an important role in the development of immunity and maintain the osmotic pressure in blood vessels, which further prevents the onset immunodeficiency disorders and hemophilia. Moreover, the widespread product adoption to treat coronavirus disease (COVID-19) patients by convalescent plasma treatment is favoring the market growth. Additionally, various technological innovations in the fractionation process that aids in separating protein concentrates and various components of blood plasma for clinical purposes are providing a considerable boost to the market growth. In line with this, the development of advanced preservation methods, along with the significant improvements in encased procedures for developing targeted therapeutic products are further augmenting the market growth. Other factors, including significant growth in the healthcare industry, increasing awareness regarding blood and plasma donation and the implementation of various government initiatives to promote blood donation camps, are anticipated to drive the market further toward growth.

Market Segmentation:

This report provides an analysis of the key trends in each segment of the global blood plasma derivatives market, along with forecast at the global, regional, and country levels from 2026-2034. The market has been categorized based on type, application, and end user.

Breakup by Type:

• Albumin
• Factor VIII
• Factor IX
• Immunoglobulin
• Hyperimmune Globulin
• Others

Breakup by Application:

• Hemophilia
• Hypogammaglobulinemia
• Immunodeficiency Diseases
• Von Willebrand's Disease
• Others

Breakup by End User:

• Hospitals
• Clinics
• Others

Breakup by Region:

• North America
• United States
• Canada
• Asia-Pacific
• China
• Japan
• India
• South Korea
• Australia
• Indonesia
• Others
• Europe
• Germany
• France
• United Kingdom
• Italy
• Spain
• Russia
• Others
• Latin America
• Brazil
• Mexico
• Others
• Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Baxter International Inc., Bayer AG, CSL Limited, Fusion Health Care Pvt. Ltd., Grifols S.A., Kedrion S.p.A., LFB S.A., Octapharma AG, Sanofi S.A. and Takeda Pharmaceutical Company Limited.

Key Questions Answered in This Report

1. What are blood plasma derivatives?

2. How big is the blood plasma derivatives market?

3. What is the expected growth rate of the global blood plasma derivatives market during 2026-2034?

4. What are the key factors driving the global blood plasma derivatives market?

5. What is the leading segment of the global blood plasma derivatives market based on type?

6. What is the leading segment of the global blood plasma derivatives market based on application?

7. What is the leading segment of the global blood plasma derivatives market based on end user?

8. What are the key regions in the global blood plasma derivatives market?

9. Who are the key players/companies in the global blood plasma derivatives market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Blood Plasma Derivatives Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Type

• 6.1 Albumin
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Factor VIII
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast
• 6.3 Factor IX
  • 6.3.1 Market Trends
  • 6.3.2 Market Forecast
• 6.4 Immunoglobulin
  • 6.4.1 Market Trends
  • 6.4.2 Market Forecast
• 6.5 Hyperimmune Globulin
  • 6.5.1 Market Trends
  • 6.5.2 Market Forecast
• 6.6 Others
  • 6.6.1 Market Trends
  • 6.6.2 Market Forecast

7 Market Breakup by Application

• 7.1 Hemophilia
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Hypogammaglobulinemia
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Immunodeficiency Diseases
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast
• 7.4 Von Willebrand's Disease
  • 7.4.1 Market Trends
  • 7.4.2 Market Forecast
• 7.5 Others
  • 7.5.1 Market Trends
  • 7.5.2 Market Forecast

8 Market Breakup by End User

• 8.1 Hospitals
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Clinics
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Others
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast

9 Market Breakup by Region

• 9.1 North America
  • 9.1.1 United States
    • 9.1.1.1 Market Trends
    • 9.1.1.2 Market Forecast
  • 9.1.2 Canada
    • 9.1.2.1 Market Trends
    • 9.1.2.2 Market Forecast
• 9.2 Asia-Pacific
  • 9.2.1 China
    • 9.2.1.1 Market Trends
    • 9.2.1.2 Market Forecast
  • 9.2.2 Japan
    • 9.2.2.1 Market Trends
    • 9.2.2.2 Market Forecast
  • 9.2.3 India
    • 9.2.3.1 Market Trends
    • 9.2.3.2 Market Forecast
  • 9.2.4 South Korea
    • 9.2.4.1 Market Trends
    • 9.2.4.2 Market Forecast
  • 9.2.5 Australia
    • 9.2.5.1 Market Trends
    • 9.2.5.2 Market Forecast
  • 9.2.6 Indonesia
    • 9.2.6.1 Market Trends
    • 9.2.6.2 Market Forecast
  • 9.2.7 Others
    • 9.2.7.1 Market Trends
    • 9.2.7.2 Market Forecast
• 9.3 Europe
  • 9.3.1 Germany
    • 9.3.1.1 Market Trends
    • 9.3.1.2 Market Forecast
  • 9.3.2 France
    • 9.3.2.1 Market Trends
    • 9.3.2.2 Market Forecast
  • 9.3.3 United Kingdom
    • 9.3.3.1 Market Trends
    • 9.3.3.2 Market Forecast
  • 9.3.4 Italy
    • 9.3.4.1 Market Trends
    • 9.3.4.2 Market Forecast
  • 9.3.5 Spain
    • 9.3.5.1 Market Trends
    • 9.3.5.2 Market Forecast
  • 9.3.6 Russia
    • 9.3.6.1 Market Trends
    • 9.3.6.2 Market Forecast
  • 9.3.7 Others
    • 9.3.7.1 Market Trends
    • 9.3.7.2 Market Forecast
• 9.4 Latin America
  • 9.4.1 Brazil
    • 9.4.1.1 Market Trends
    • 9.4.1.2 Market Forecast
  • 9.4.2 Mexico
    • 9.4.2.1 Market Trends
    • 9.4.2.2 Market Forecast
  • 9.4.3 Others
    • 9.4.3.1 Market Trends
    • 9.4.3.2 Market Forecast
• 9.5 Middle East and Africa
  • 9.5.1 Market Trends
  • 9.5.2 Market Breakup by Country
  • 9.5.3 Market Forecast

10 SWOT Analysis

• 10.1 Overview
• 10.2 Strengths
• 10.3 Weaknesses
• 10.4 Opportunities
• 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

• 12.1 Overview
• 12.2 Bargaining Power of Buyers
• 12.3 Bargaining Power of Suppliers
• 12.4 Degree of Competition
• 12.5 Threat of New Entrants
• 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

• 14.1 Market Structure
• 14.2 Key Players
• 14.3 Profiles of Key Players
  • 14.3.1 Baxter International Inc.
    • 14.3.1.1 Company Overview
    • 14.3.1.2 Product Portfolio
    • 14.3.1.3 Financials
    • 14.3.1.4 SWOT Analysis
  • 14.3.2 Bayer AG
    • 14.3.2.1 Company Overview
    • 14.3.2.2 Product Portfolio
    • 14.3.2.3 Financials
    • 14.3.2.4 SWOT Analysis
  • 14.3.3 CSL Limited
    • 14.3.3.1 Company Overview
    • 14.3.3.2 Product Portfolio
    • 14.3.3.3 Financials
    • 14.3.3.4 SWOT Analysis
  • 14.3.4 Fusion Health Care Pvt. Ltd.
    • 14.3.4.1 Company Overview
    • 14.3.4.2 Product Portfolio
  • 14.3.5 Grifols S.A.
    • 14.3.5.1 Company Overview
    • 14.3.5.2 Product Portfolio
    • 14.3.5.3 Financials
    • 14.3.5.4 SWOT Analysis
  • 14.3.6 Kedrion S.p.A.
    • 14.3.6.1 Company Overview
    • 14.3.6.2 Product Portfolio
  • 14.3.7 LFB S.A.
    • 14.3.7.1 Company Overview
    • 14.3.7.2 Product Portfolio
  • 14.3.8 Octapharma AG
    • 14.3.8.1 Company Overview
    • 14.3.8.2 Product Portfolio
    • 14.3.8.3 SWOT Analysis
  • 14.3.9 Sanofi S.A.
    • 14.3.9.1 Company Overview
    • 14.3.9.2 Product Portfolio
    • 14.3.9.3 Financials
    • 14.3.9.4 SWOT Analysis
  • 14.3.10 Takeda Pharmaceutical Company Limited
    • 14.3.10.1 Company Overview
    • 14.3.10.2 Product Portfolio
    • 14.3.10.3 Financials
    • 14.3.10.4 SWOT Analysis